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Abbreviations 
ALS: Advanced Life Support 
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Introduction 
Nausea and vomiting (N&V) are common complaints that result in patients seeking 
emergency medical treatment[1–3] .N&V have a variety of causes, which explains why 
it is such a common illness[1, 2]. N&V can be caused by medications such as opioids, 
cancer chemotherapeutic agents, cardiovascular agents, anticonvulsants; disorders 
of the gastrointestinal tract (GIT) such as bowel obstruction, cholecystitis, 
gastroparesis, irritable bowel syndrome; central nervous system disorders such as 
migraine, raised intracranial pressure and hydrocephalus[1]. Alcohol was also found 
to be a major contributor to N&V in a healthy population[3]. 
The experience of N&V is potentially distressing to the patient. As a result, drug 
therapy, to treat nausea and vomiting, in the emergency care setting, is often needed 
to improve patient care and comfort[4]. Furthermore, vomiting presents a considerable 
risk of airway compromise due to aspiration[2, 5]. The administering of an antiemetic 
has the potential to not only improve patient care and comfort, but to mitigate against 
complications such as: electrolyte imbalances, dehydration, and aspiration of gastric 
contents[6]. In a 2011 cross-sectional survey conducted by Mee et al[4], Fellows of 
the Australasian College for Emergency Medicine were asked to describe their most 
common first-, second-, and third-line antiemetic drug choice; it was found that  
metoclopramide was found to be the drug of first choice to treat N&V in the emergency 
centre (EC)[4]. Data from this study showed that the main influences on antiemetic 
choice was patient age, perceived effectiveness of therapy, and side effect profile of 
the drug[4]. 
Advanced life support (ALS) paramedics in South Africa (SA) only have 
metoclopramide available to them to use as an antiemetic[7]. Metoclopramide has 
been used for many years to treat N&V in the emergency care setting[4, 7], but as 
evidence-based medicine has evolved, healthcare practitioners need to reconsider the 
use of metoclopramide and phenothiazines such as prochlorperazine (or even other 
agents such as  ondansetron which would more recently (2018) seem to be the 
preferred agent amongst Australian prehospital practitioners[8]) in the treatment of 
post analgesia nausea and vomiting.  
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Aims 
In 2006 Sanger and Andrews[9] conducted a review on the treatment of nausea and 
vomiting[9] in which they   reviewed the literature on the pharmacology, knowledge 
surrounding and the identified gaps in the treatment of nausea and vomiting[9]. They  
concluded that identifying a suitable anti-nausea drug is problematic and nausea is 
poorly treated[9], thus prompting this scoping review. This scoping review aims to 
review and map the available literature on the use of metoclopramide and 
prochlorperazine in treating nausea and vomiting in the emergency setting. The 
objective of this review is to provide recommendations on the selection of either 
metoclopramide or prochlorperazine to treat nausea and vomiting in the emergency 
setting  
Search strategy   
For the purpose of this literature review the researcher undertook a limited literature 
search to help build the background and rationale for the scoping review. The 
following online databases Pubmed, Medline, Embase Cochrane databases, 
CINAHL, Web of Science, TRIP and EBSCO host were searched. Identifiable MESH 
search terms such as “nausea”, “vomiting”, “emergency care setting”, “prehospital”, 
“emergency medical services”, “metoclopramide”, “prochlorperazine”, “motion-
sicknesses”, “emergency department”, “paramedic”, “ambulance”, “ambulance 
services”, “visual analogue scale”, “assessment nausea and vomiting”, “mechanism 
of nausea and vomiting”, “pathophysiology nausea”, “ pathophysiology vomiting”  
was used to search for relevant literature. To improve search sensitivity the above 
search terms were entered in various combinations and truncated forms.   
Articles were sourced from peer reviewed journals that are published in English, using 
databases such as Medline, PUBMED and Scopus. Patents, text references, animal 
studies, research older than 1989 were filtered out. Articles found relevant to this study 
were used to generate further literature. Background information was also sought from 
a variety of clinical and pharmacological textbooks. Inclusion criteria for selected 
literature was as follows: 
• English print 
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• Peer reviewed articles 
• Research conducted in the prehospital environment 
• Research conducted in the emergency centre (EC) 
• Case studies, Randomised control trials (RCT), systematic reviews, pharmacopeia 
textbooks  
The search period was conducted from 1989 up to and including December 2018.   
Prevalence and risk factors of nausea and vomiting 
Nausea is a subjective sensation[1, 10]. It is an urge to vomit, and when severe it is 
associated with increased salivary secretions, sweating and vasomotor 
disturbances[10]. Vomiting is the forceful expulsion of gastric contents through the 
mouth[10]. Anxiety, gender, age, history of being sick after alcohol consumption, 
history of vertigo, medication usage, opioid administration are some of the risk factors 
associated with nausea and vomiting[10] 
In a population based survey done by Rub et al[3] in 1992, the authors surveyed 596 
participants, recruited from a variety of community groups, to understand the 
prevalence of nausea and vomiting in a healthy population[3]. Data from this survey 
revealed that alcohol was a major contributing factor to nausea and vomiting in a 
healthy population[3]. Following the study by Rub et al[3], in 2002, in Nord-Trøndelag, 
a county in Norway, a population based study on the prevalence of nausea was 
conducted by  Haug et al[11]. Data from this study showed that from a population base 
of 94 197 inhabitants in Nord-Trøndelag at the time of the survey, 65% had 
gastrointestinal (GI) symptoms, and 12.5% of the population had complained of 
nausea in the year preceding the survey. This study also revealed that nausea for 
women was three times higher than that for man[11].  
Ethnicity has also been identified as a risk factor for nausea and vomiting[12–14]. In a 
2010 study conducted by Rodseth et al[12] in South Africa, the author aimed to test 
the hypothesis that the occurrence of postoperative nausea and vomiting differs 
between African South Africans and the non-African South African patient[12]. Data 
from this study showed that from a sample size of 547 patients, of which 308 were 
African and 239 were non-African, the incidence of post-operative nausea and 
vomiting was 22% in the African group and 44% in the non-African group[12]. The 
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effect of ethnicity on the incidence of post-operative nausea and vomiting was further 
investigated in two more studies. In a 2015 study conducted  in a Singapore hospital, 
the effect of ethnicity on post-operative nausea and vomiting in elective orthopaedic 
cases was investigated by Leong et al[13]. From a cohort of 785 patients, post-
operative nausea and vomiting occurred in 261 patients, of which 91 were Chinese, 
89 were Malay, 76 were Indian, and 5 were other ethnicity[13].  In 2017 another South 
African study done by Alli et al[14] found that from a sample size 94 patients with 5 
exclusions, non-African patients had a 25 times higher incidence of nausea than 
African patients[14].  
Nausea and vomiting can also be caused by various motion environments[15]. 
Ethnicity and gender has been shown to influence motion sickness in a 2006 study by 
Klosterhalfen et al[16]. Data from this study showed that from a study population of 48 
adults, of which 24 were Chinese and 24 were White[16]. Data from this study showed 
that Chinese participants reported significantly fewer symptoms than White 
participants[16].    
Motion sickness can also occur during ambulance transport of patients, and is often 
associated with nausea and vomiting[17]. In 2012 Easton et al[18] conducted a 
prospective study, with sample size of 196 adult patients that was transported by 
ambulance to EC over a five month period[18]. Patients were asked whether they had 
experienced nausea at the scene, during ambulance transportation, or immediately 
upon arrival at the EC[18]. Data showed vomiting in 15  patients, nausea in 75 patients 
of which 57  patients reporting moderate to severe nausea[18]. From the 90 patients 
that reported nausea and vomiting a  total of 63 patients received an antiemetic, of 
which 52 patients received the antiemetic in the prehospital phase[18]. Also in  this 
study 79 patients were given an antiemetic prophylactically, of which metoclopramide 
was given to 76 of those 79 patients[18]. Furthermore, data from this study showed 
that factors most likely to influence nausea and vomiting are: female gender, age, 
weight, injury severity score transport time, opioid analgesic use and pain score[18].  
Assessment of nausea 
Nausea and vomiting is a subjective sensation, and an accurate assessment can only 
be given by the patient[19]. The severity of nausea and vomiting is commonly 
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assessed using either a discrete scale (DS), a visual analogue scale(VAS), or  the 
analogue continuous chromatic scale(ACCS)[20–23] in which patients are asked to 
describe their N&V[20, 23]. With the DS, the patient is asked to rate their nausea as 
0=no nausea, 1= slight nausea, 2= moderate nausea, and 3= severe nausea[20]. In 
the VAS, the patient is asked to move a marker along a 100mm vertical line, with “no 
nausea”=0 marked at the bottom and “the worst ever nausea”= 100 marked at the 
top[20]. Similar to the VAS, the ACCS consists of a coloured horizontal strip 100mm 
long and 25mm wide, and patients rate their nausea by moving a slider from the left 
(no nausea) to the right (worst ever nausea)[20]. 
 In an attempt to provide validity on the existing methods of assessing nausea and 
how best to use these methods in clinical trials on antiemetics, a study was conducted 
by Del Favero et al[20] in 1990[20]. In this study, they reviewed six trials (four double 
blind RCT, two observational studies)[20] where they compared the discrete scale, the 
visual analogue scale (VAS) and the analogue continuous chromatic scale [20]. This 
study used Spearman’s correlation coefficient to evaluate the correlation between the 
three scales in assessing the dimensions of nausea[20]. There was good correlation 
between the DS and the VAS (r=0.68) in assessing the maximal intensity of 
nausea[20]. The degree of correlation between the VAS and ACCS, the two analogue 
scales, was even better than the degree of correlation between the DS and the VAS 
(r=0.74 and r=0.68 respectively)[20]. Further to this, this study found that there was no 
clear advantage of using any particular scale over another, and that the VAS gives a 
more uniform distribution of baseline maximal intensity nausea values, and a greater 
sensitivity in assessment of the variations of the same values in patients that are 
treated for nausea and vomiting[20]. 
The VAS, as described above, was evaluated again in another study done by 
Boogaerts et al[21] in 2000[21]. In this study, 128 consecutive inpatients, complaining 
of spontaneous post-operative nausea and vomiting were studied[21]. Comparison of 
VAS measurements was done by the Student paired t-test, and the symmetry test was 
used for the DS[21]. Nausea intensity in this study was assessed using the VAS and 
the DS[21].  and the VAS proved to be a useful scale to quantitatively assess the 
intensity of nausea as well as the efficacy of rescue medication in relieving the 
symptoms of nausea in patients[21]. Meek et al[22] conducted a prospective 
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observational study in 2009, assessing nausea and vomiting in the EC population[22]. 
Meek et al[22] assessed the association between verbal descriptors for nausea and 
vomiting and the VAS rating[22]. Correlation between VAS and verbal descriptors was 
assessed using the Spearman rank correlation coefficient[22]. It was found that there 
was a good correlation between the two, and VAS is a practical scale to use[22]. 
In 2011 a literature review was done by Wood et al[23] with the objective of providing 
an a comprehensive overview of the different tools used to evaluate N&V in 
chemotherapy patients[23]. No single assessment tool for N&V was found to be 
superior than any other assessment tool in this review[23]. The VAS was found to be 
clinically useful and easy to understand for the patient[23].  
The VAS can provide the clinician with the relevant real-time information needed in 
assessing a patients N&V[23]. It does not place an additional burden on the already 
nauseated patient, by expecting the patient to answer numerous questions or go 
through a lengthy assessment of his/her nausea, making it useful to use in the 
emergency setting 
Management of nausea and vomiting 
The management of the patient presenting with nausea and vomiting should include 
a systematic approach that includes correcting any electrolyte imbalance, correcting 
fluid and nutritional deficiencies, and then identifying and eliminating the source of the 
nausea and vomiting (where possible)[24–26]. The administration of an antiemetic 
agent can be helpful in managing as well as limiting the risks from N&V[1, 25]. 
Medical treatment for N&V generally falls into two categories. There are therapies that 
focus on the suppression of nausea and vomiting, and therapies that focus on 
promoting gastric motility[1]. Commonly used antiemetic agents, as shown in Table 2,  
can be grouped into different classes of drugs[1, 27] 
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Table One. Common antiemetic agents. Adapted from Prashant Singh, Sonia S. Yoon and Braden Kuo, Nausea: a review of 
pathophysiology and therapeutics Ther Adv Gastroenterol 2016, Vol. 9(1) 98 –112 
 Drug Mechanism of action Adverse effects Indication  
Antihistamine 
 
 
 
 
 
 
 
 
 
 
 
Meclizine  Acts on central anticholinergic and 
antihistamine receptors (M1 and H1 
receptors). Labyrinthine and vestibular 
stimulation is suppressed. 
Drowsiness confusion blurred vision 
constipation urinary retention  
Indicated for motion sickness, vertigo, and 
nausea and vomiting caused by 
labyrinthine disorders 
Diphenhydramine Acts on central anticholinergic and 
antihistamine receptors (M1 and H1 
receptors). Labyrinthine and vestibular 
stimulation is suppressed. 
Drowsiness confusion blurred vision 
constipation urinary retention 
Indicated for motion sickness, vertigo, and 
nausea and vomiting caused by 
labyrinthine disorders 
Cyclizine Acts on central anticholinergic and 
antihistamine receptors (M1 and H1 
receptors). Labyrinthine and vestibular 
stimulation is suppressed. 
 
Drowsiness confusion blurred vision 
constipation urinary retention 
Indicated for motion sickness, vertigo, and 
nausea and vomiting caused by 
labyrinthine disorders. 
Phenothiazine 
Prochlorperazine Antidopaminergic agents. Act via 
nonselective inhibition of D2 and D3 
receptors. They also act muscarinic and 
H1 receptors 
Extrapyramidal side effects, tardive 
dyskinesia neuroleptic malignant 
syndrome prolonged QT interval, 
increased prolactinemia  
Indicated for nausea and vomiting related 
to migraine, motion sickness, vertigo, as 
well as post-operative nausea and 
vomiting 
Promethazine Antidopaminergic agents. Act via 
nonselective inhibition of D2 and D3 
receptors. They also act muscarinic and 
H1 receptors 
Extrapyramidal side effects, tardive 
dyskinesia neuroleptic malignant 
syndrome prolonged QT interval, 
increased prolactinoma  
Indicated for nausea and vomiting related 
to migraine, motion sickness, vertigo, as 
well as post-operative nausea and 
vomiting 
Chlorpromazine Antidopaminergic agents. Act via 
nonselective inhibition of D2 and D3 
receptors. They also act muscarinic and 
H1 receptors 
Extrapyramidal side effects, tardive 
dyskinesia neuroleptic malignant 
syndrome prolonged QT interval, 
increased prolactinemia  
Indicated for nausea and vomiting related 
to migraine, motion sickness, vertigo, as 
well as post-operative nausea and 
vomiting 
Benzamides 
Metoclopramide Dopamine D2 receptor antagonist, 
enhances upper GI motility and promotes 
gastric emptying due to its prokinetic 
Sedation, anxiety, altered mood, 
sleep disruption, dystonic reactions, 
Indicated for post-chemotherapy 
associated nausea and vomiting 
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effect. It also works as a vagal receptor 
and 5-HT3 receptor antagonist and a 5-
HT4 agonist 
tardive dyskinesia, galactorrhoea, 
sexual dysfunction 
Domperidone Dopamine D2 receptor antagonist, 
enhances upper GI motility and promotes 
gastric emptying due to its prokinetic 
effect. It also works as a vagal receptor 
and 5-HT3 receptor antagonist and a 5-
HT4 agonist 
Does not cross the blood brain barrier 
Galactorrhoea, sexual dysfunction Indicated for post-chemotherapy 
associated nausea and vomiting 
5-HT3 
antagonists 
Ondansetron Antagonistic effects on the 5-HT3 
receptor in the CTZ 
Headaches, fatigue, malaise, 
constipation 
First line agent used for common causes of 
acute nausea 
Granisetron Antagonistic effects on the 5-HT3 
receptor in the CTZ 
Headaches, fatigue, malaise, 
constipation 
First line agent used for common causes of 
acute nausea 
Tropisetron Antagonistic effects on the 5-HT3 
receptor in the CTZ 
Headaches, fatigue, malaise, 
constipation 
 
 
 
 
Cannabinoids 
Dronabinol Act primarily through the canniboid 
receptor in the medulla and the area sub 
postrema of the nucleus tractus solitarius 
Palpitations, tachycardia, flushed 
face, euphoria, dizziness, visual 
disturbances, paranoia 
Investigated in chemotherapy associated 
nausea and vomiting 
Nabilone  Act primarily through the canniboid 
receptor in the medulla and the area sub 
postrema of the nucleus tractus solitarius 
Palpitations, tachycardia, flushed 
face, euphoria, dizziness, visual 
disturbances, paranoia 
Investigated in chemotherapy associated 
nausea and vomiting 
Benzodiazepin
es 
Lorazepam Acts by reducing the anticipatory 
component of nausea associated with 
chemotherapy 
Cognitive dysfunction, depression, 
dizziness, drowsiness, irritability, 
impaired memory, sedative effects 
Adjunctive therapy in postoperative 
nausea and vomiting, 
Alprazolam Acts by reducing the anticipatory 
component of nausea associated with 
chemotherapy 
Cognitive dysfunction, depression, 
dizziness, drowsiness, irritability, 
impaired memory, sedative effects 
Adjunctive therapy in postoperative 
nausea and vomiting, 
Butyrophenon
es 
Droperidol Acts via antidopaminergic activity in the 
CTZ 
Prolonged QTc, orthostatic 
hypotension, extrapyramidal 
symptoms 
Indicated for postoperative nausea and 
vomiting 
NK-1 Receptor 
antagonists 
Aprepitant Potentiates the effects of the 5-HT3 
receptor antagonist, tachykinin receptor 
antagonist 
Fatigue, constipation, hiccups Indicated for delayed chemotherapy 
induced nausea and vomiting 
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Corticosteroids Dexamethasone Mechanism of action not completely 
known.  
Emotional disturbances, acne, 
hyperglycaemia, Cushing’s syndrome 
Indicated for postoperative nausea and 
vomiting 
Anticholinergic Scopolamine Muscarinic type one receptor antagonist Tachycardia confusion dry mouth 
constipation urinary retention blurred 
vision 
Mainly used for its antispasmodic action 
CTZ: chemoreceptor trigger zone; GI: gastrointestinal; mg: milligrams; kg: kilograms; NK-1: neurokinin 1 ; M1: Muscarinic 1 ; H1: Histamine receptor; D2: 
dopamine receptor; D3 : dopamine receptor 
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The focus of the remainder of this review is on the comparison of metoclopramide 
and prochlorperazine. Metoclopramide as well as prochlorperazine have both been 
long  established antiemetics and have been widely used for the treatment of mild to 
moderate N&V[24, 28]. They have shown to be effective in postoperative as well as 
post-chemotherapy induced N&V[24, 28]. As well as being an antiemetic, 
metoclopramide is a prokinetic as well, and because of this dual action, it is 
particularly useful for gastric emptying before emergency surgery[28]. Unlike 
metoclopramide[28], prochlorperazine has been effective in treating N&V that is 
caused by motion sickness[24, 28]. Both these drugs are readily available in South 
Africa[28]. Both are easy to administer in the emergency care setting, and can be 
administered intravenously and intramuscularly[28]. Both these agents can be used 
as antiemetics in the emergency setting, but which is the better agent? 
Antiemetic effectiveness  
There are several well established, commonly used antiemetic drugs, but this is a 
rapidly evolving field. Likely fed by newer drugs and modalities used with 
chemotherapeutic agents, and from peri-operative use. Comparing the efficacies of 
drugs has been the focus of many studies, and here some are examined, with the 
focus on those studies including metoclopramide and prochlorperazine. The majority 
of studies are not from the prehospital context, and this needs to be borne in mind. 
Metoclopramide was evaluated by Lambie et al[29]; Talbot-Stern et al[30]; Cham et 
al[31]; Bradshaw and Sen[32]; Braude et al[33]; Chae et al[34]; Barret et al[35]; 
Rubio et al[36] and Egerton-Warburton et al[37]. Prochlorperazine was evaluated by 
Ernst et al[38]; Braude et al[33] and Patka et al[39].   
USE OF METOCLOPRAMIDE IN THE EC 
In a pilot study conducted in 2004 in an EC with an annual patient volume of 75000 
patients, by Cham et al[31] the effectiveness of metoclopramide to treat N&V using 
different dosing regiments was evaluated[31]. Patients received either 0.4mg/kg 
intermediate dose or the standard 10mg dose[31]. A total of 58 patients were enrolled 
in this study, where 34 patients received 10mg metoclopramide and 24 patients 
received 0.4mg/kg dose[31]. The mean reduction in nausea for the 10mg group was 
four and for the 0.4mg/kg group it was five[31]. The author found no difference in 
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effectiveness to treat nausea if patients received the standard dose or the intermediate 
dose of metoclopramide[31]. 
In 2006 Braude et al[33] compared metoclopramide to prochlorperazine, droperidol 
and a placebo in a study conducted in an urban EC with an annual patient volume of 
55000[33]. . This study enlisted 97 patients of which 25 received metoclopramide, 22 
received droperidol, 24 received prochlorperazine, and 26 received a placebo[33]. The 
primary outcome of this study was a reduction in VAS scores for nausea[33]. Data 
from this study showed that metoclopramide resulted in a mean change in VAS of 
(mean ±standard deviation) -40.2 ± 23.8mm from baseline, prochlorperazine -40.5 ± 
24.1mm, and droperidol  -54.5 ± 18.4mm, all taken 30 minutes after the study drug 
was administered[33]. Secondary outcome measures reported in the study by Braude 
et al[33], were nausea, anxiety and sedation[33]. The author of this study concluded 
that 1.25mg droperidol, when administered intravenously to patients with moderate to 
severe nausea, was more effective then when patients received either 10mg 
metoclopramide or 10mg prochlorperazine[33].  
In 2011, a study conducted in an EC with an annual patient volume of 70000 patients 
was done by Chae et al[34], evaluating metoclopramide and tropisetron for the 
treatment of nausea and vomiting[34]. This study enlisted 100 patients with 50 patients 
in the metoclopramide group and 50 patients in the tropisetron group[34]. The primary 
end point in this study was the incidence of vomiting, and the secondary end points 
was decrease in nausea score from baseline, rescue medication requirements, 
adverse effects, unresolved nausea, and antiemetic requirements 48 hours post 
discharge from EC[34]. Data from this study showed that two patients in the tropisetron 
group and nine patients in the metoclopramide group had vomited at 180 minutes from 
the baseline[34]. Further to this, the decrease in the mean VAS nausea scores from 
baseline was slightly higher for metoclopramide -26.4mm than for tropisetron -25.2mm 
at 30 minutes[34]. In this study, data also showed that the mean akathisia scores for 
metoclopramide was higher than that for tropisetron[34]. Mean akathisia for 
metoclopramide was 1.70 and 0.57 for tropisetron at 30 minutes[34]. From the results 
of this study the authors concluded that tropisetron was associated with lower vomiting 
rates and reported akathisia than metoclopramide[34]. The authors also concluded 
that tropisetron had better nausea control than metoclopramide[34] 
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In 2011 in an urban university-affiliated adult EC with an annual patient volume of 
54000 patients Barret et al[35] conducted a four arm placebo controlled study 
evaluating metoclopramide, promethazine and ondansetron[35]. The distribution of 
patients to the various treatment arms were as follows: metoclopramide 43, 
promethazine 45, ondansetron 42 and saline placebo 41 patients[35]. The primary 
outcome of this study was a change in VAS score from a baseline to 30 minutes This 
study found a mean reduction in VAS scores to be -30mm (95%CI= -38 to -25.5mm), 
-22mm (95%CI= -32mm to -15mm), -29mm (95%CI= -40mm to -21mm), -16mm 
(95%CI= -25mm to -3mm) for metoclopramide, ondansetron, promethazine and saline 
respectively[35]. Akathisia, headache, pain at intravenous site, and sedation were the 
reported side effects in this study[35]. Data showed that the occurrence of akathisia 
was highest in the metoclopramide treatment arm followed by ondansetron, 11 for 
metoclopramide and five for ondansetron and two for promethazine[35].The 
conclusion of this study, was that ondansetron is not superior to metoclopramide or 
promethazine in reducing nausea in the EC patients[35].  
In 2014, Egerton-Warburton et al[37] conducted a prospective RCT in two EC’s. The 
first EC being a tertiary EC receiving 70000 patients annually and the second EC being 
a district EC receiving 57000 patients annually[37]. A total of 258 patients were 
recruited of which 87 received ondansetron, 88 received metoclopramide, and 83 
received a placebo[37]. The primary outcome of this study was a change in VAS 30 
minutes post administration of the study drug[37]. This study found the mean decrease 
in VAS was 28mm (95%CI= 22-34mm) for metoclopramide, 27mm (95%CI= 22-
33mm) for ondansetron, and 23mm (95%CI= 16-30mm) for placebo[37]. Furthermore, 
in this study it was found that nine patients reported adverse an adverse event[37]. 
Data showed that six of these patients were from the metoclopramide group: two 
patients reported akathisia, two patients reported restlessness, one patient reported 
muscle twitching, and one patient had sweatiness[37]. From the ondansetron group, 
one patient had dizziness, and one patient has stinging/burning at the injection 
site[37]. In the placebo group only one patient reported shaking/restlessness[37]. The 
authors of this study concluded that reductions in nausea severity were similar for 
ondansetron, metoclopramide and the placebo group[37].  
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Even though metoclopramide has shown it is effective in reducing nausea and 
vomiting[33–35, 37], it has not shown superiority to any other antiemetic.   
USE OF METOCLOPRAMIDE IN THE PREHOSPITAL SETTING 
 In a 2011 prehospital study  in America, metoclopramide, diphenhydramine and a 
placebo were compared to each other in the treatment of motion sickness by Rubio et 
al[36]. The aim of this study was to determine if metoclopramide or diphenhydramine 
would help relieve the symptoms of motion sickness when patients are transported in 
an ambulance to hospital[36]. The closest receiving hospital was 40 minutes from the 
ambulance station[36]. Only patients who developed signs and symptoms of motion 
sickness was given either metoclopramide, diphenhydramine or the placebo[36]. 
Twenty six patients were enrolled into this study, of which 22 patients developed 
motion sickness[36]. The high incidence of motion sickness in this study could possibly 
be attributed to the fact that the patients being transported was already sick, and this 
predisposed them to developing motion sickness[36]. From the 22 patients, seven 
patients were placed in the placebo group, seven patients in the diphenhydramine 
group and eight patients in the metoclopramide group[36]. Over time, all three drugs 
showed a significant reduction in their mean VAS from baseline, however 
metoclopramide showed a statistically significant decrease in VAS at 15 minutes after 
the initial dose of medication was given[36]. Mean VAS for nausea for the 
diphenhydramine group was 46.9 (95%CI = 29.2-64.6) at 15 minutes, whilst the mean 
VAS for the placebo group was, 51.4 (95%CI = 37.1-65.7) at 15 minutes and 
metoclopramide showed a mean VAS of 7.4 (95%CI = 4.1-10.7) at 15 minutes [36]. 
From the data in this study, the authors concluded that metoclopramide is superior in 
treating motion sickness when compared to diphenhydramine and a placebo[36].  
USE OF METOCLOPRAMIDE PROPHYLACTICALLY WITH OPIOIDS 
Metoclopramide can also be given prophylactically to a patient to prevent nausea and 
vomiting when an opioid analgesic is administered[29, 30, 32]. In 1999, an EC study 
to determine if the routine administration of metoclopramide to patients who received 
intravenous morphine was of benefit to the patient, was conducted by Lambie et al[29]. 
Patient throughput was not reported in this study. A total of  214 patients were enrolled, 
of which 111 patients received prophylactic metoclopramide and 103 patients received 
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a placebo prior to receiving morphine[29]. Data from this study showed that two 
patients in the placebo group reported severe nausea and no patients in the 
metoclopramide group reported nausea[29]. No adverse effects were reported in this 
study[29]. The authors of this study concluded that routine use of an antiemetic for 
patients receiving intravenous morphine for musculoskeletal trauma is not 
justifiable[29]. 
In 2000 a study to investigate the potential value of administering metoclopramide 
prophylactically to patients and the incidence of nausea and vomiting after an 
intravenous opioid analgesic was administered was done by Talbot-Stern and 
Paoloni[30]. This study was conducted in a tertiary referral EC that has approximately 
45000 patients annually[30]. A total of 127 patients were enrolled into this study, where 
63 patients received metoclopramide and 59 patients received a placebo immediately 
after receiving and opioid analgesic[30]. The results from this study showed that at 30 
minutes three patients in the metoclopramide group and five patients in the placebo, 
and at 60 minutes four patients in the metoclopramide group and four patients in the 
placebo group reported nausea[30]. In addition to this, the data from this study also 
showed that 7.9% of the patients in the metoclopramide group reported adverse 
effects such as dystonic reactions, vertigo, dizziness lasting more than an hour, 
restlessness and drowsiness[30]. The authors of this study recommended that 
prophylactic metoclopramide should not be routinely used[30]. 
In 2006 an EC study enrolling 259 patients comparing the incidence of nausea and 
vomiting in patients that received either metoclopramide or a placebo prophylactically 
when they were given intravenous morphine for acute pain, was conducted by 
Bradshaw and Sen[32]. In this study 123 patients received metoclopramide and 136 
patients received a placebo before receiving morphine[32]. Data from this study 
showed that two patients in the metoclopramide group and five patients in the placebo 
group had nausea[32]. No adverse events were recorded in this study. The authors 
concluded that the incidence of nausea and vomiting is low irrespective of whether or 
not the patient received metoclopramide[32]. 
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The prophylactic use of metoclopramide when a patient receives an opioid analgesic 
cannot be justified[29, 30, 32]. The administration of metoclopramide unnecessarily 
exposes the patient to the adverse effects of metoclopramide[29, 30, 32]  
USE OF PROCHLORPERAZINE IN THE EC 
Prochlorperazine was evaluated in three EC studies for its use in the treatment of 
nausea and vomiting[33, 38, 39]. Only one study evaluated prochlorperazine and 
metoclopramide[33]. 
In 2000 prochlorperazine was compared to promethazine in the treatment of nausea 
and vomiting caused by gastritis or gastroenteritis by Ernst et al[38]. This study was 
conducted in two academic EC units but only managed to enrol 84 patients[38]. The 
main outcome measure was relief of nausea at 30 and 60 minutes[38]. Akathisia and 
drowsiness were also reported in this study[38]. Data showed that at 30 minutes 
prochlorperazine was much better than promethazine at relieving nausea with a 
median change in VAS of 4.5 vs 2.7 respectively[38], however at 60 minutes 
promethazine showed better VAS ratings than prochlorperazine with a median change 
in VAS of 2 vs 1.55 respectively[38]. Data from this study also showed that 16 pts that 
received prochlorperazine vs 30 pts in the promethazine group reported drowsiness 
and 6 pts each in both groups reported akathisia[38]. The conclusion of this study was 
that prochlorperazine was more effective than promethazine in treating uncomplicated 
nausea[38]. 
Following the study by Ernst et al[38], in 2011 prochlorperazine was compared to 
ondansetron in its effectiveness to treat vomiting in adults presenting to the EC with 
nausea and vomiting by Patka et al[39]. A total of 64 patients were enrolled in this 
study, 32 patients in the ondansetron group and 32 patients in the prochlorperazine 
group[39]. The primary outcome of this study was the percentage of patients with 
vomiting at 30, 60, and 120 minutes post administration of ondansetron or 
prochlorperazine[39]. Secondary outcome measures included nausea at 30, 60,  and 
120 minutes as well as percentage of patients experiencing sedation, headache, 
akathisia and dystonia[39].  Data from this study revealed that overall more patients 
receiving ondansetron had experienced breakthrough vomiting seven patients vs two 
patients. In addition to this, patients that had received prochlorperazine reported lower 
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mean nausea scores post receiving prochlorperazine or ondansetron[39]. Mean  VAS 
nausea scores reported were, 47.5mm vs 50.4mm at 30 minutes, 24.9mm vs 43.7mm 
at 60 minutes and 16.8mm vs 34.3mm at 120 minutes  for prochlorperazine vs 
ondansetron respectively[39]. Four cases of akathisia was reported in this study, three 
in the prochlorperazine group and one patient in the ondansetron group[39]. The 
authors of this study concluded that prochlorperazine and ondansetron are equally 
effective in treating nausea and vomiting[39].  
Prochlorperazine has shown to be more effective than promethazine in treating 
nausea, but it has not shown to be more effective than metoclopramide in treating 
N&V[33, 38].  
Rescue medication 
Rescue medication, is medication administered to patients, to produce relief from the 
symptoms of an  acute onset medical condition when these patients have a 
poor response to the initial drug administered[40]. This rescue medication can be 
administered either alone or in combination with the first drug that was 
administered[40]. 
The reporting of the use rescue medication is not consistent and not well reported in 
the selected studies for this review[29, 31–35, 37–39]. The choice of drug that was 
chosen as a rescue antiemetic was not reported in all the trials. From all the studies 
selected, only three studies, Bradshaw and Senl[32], Lambie et al[29], and Rubio et 
al[36], documented what the rescue drug was. For  Bradshaw and Sen[32] and Lambie 
et al[29] it was cyclizine and for Rubio et al[36] it was metoclopramide. This is an 
important finding, because it gives an indication to the efficacy of the antiemetic used 
in the trial[8].  
The prehospital environment 
From the studies selected in this review it is only the study by Rubio et al[36] that was 
conducted in the prehospital setting. The other studies were all conducted in hospital 
emergency centres. This shows that there is very limited literature on prehospital 
antiemetic use.  
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Trauma patients are generally transported to hospital lying flat on a stretcher in the 
back of an ambulance[41][42].The ALS paramedic in South Africa is trained to treat 
patients complaining of nausea and vomiting related to gastrointestinal disorders, or 
nausea and vomiting that is caused by the administration of morphine[7]. The ALS 
paramedic needs an effective, low cost, easy to administer antiemetic in the 
prehospital patient presenting with nausea and vomiting. This is paramount to safe 
and effective patient management. Currently the only drug available to the ALS 
paramedic is metoclopramide. From the evidence found in this review the prophylactic 
use of metoclopramide when a patient is given an opioid analgesic cannot be 
justified[29, 30, 32].  .. 
Conclusion 
From the literature found for this review, it is evident that there is no clear evidence for 
any single antiemetic being the best option to treat nausea and vomiting in the 
emergency setting. There is very little literature available from studies conducted in 
the prehospital setting on treating nausea and vomiting, and hence much of the 
evidence is extrapolated from hospital emergency patients. There has been no study 
conducted on the use of prochlorperazine for treating nausea and vomiting in the 
prehospital environment. From the available literature found on metoclopramide and 
prochlorperazine use to treat nausea and vomiting in the emergency setting only three 
studies evaluated prochlorperazine. Even though both metoclopramide and 
prochlorperazine are effective in treating N&V, neither metoclopramide nor 
prochlorperazine has proven to be better at treating N&V.   Further research especially 
in the prehospital setting is required, in order to allow an evidence-based 
reconsideration of the range of antiemetics available for prehospital practitioners.  
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Abstract    
 
Introduction 
Nausea and vomiting are a common complaint with a wide variety of aetiologies. Patients 
frequently present to emergency care providers seeking treatment for nausea and vomiting. 
Metoclopramide and prochlorperazine are well established drugs that have long been used in 
the treatment of nausea and vomiting. This scoping review aims to map out the available 
literature on metoclopramide and prochlorperazine in treating nausea and vomiting in the 
emergency setting, and more specifically for prehospital use.  
Methods 
A broad literature search was conducted using the following search terms “nausea”, 
“vomiting”, “emergency care setting”, “prehospital”, “motion sickness”, “emergency medical 
services”, “metoclopramide”, “prochlorperazine”, was done on online databases such as 
Pubmed, Medline, Embase Cochrane databases, CINAHL, Web of Science, TRIP and 
EBSCO host.  
Results 
A total of 11 articles were found published between 1989 and 2014. Ten studies were found 
from emergency centres and just one from the prehospital setting. Six studies originated in 
America, three in Australia, one in the United Kingdom, and one in New Zealand. The total 
number of patients in the 11 included studies were 1319 subjects, where 511 received 
metoclopramide, 448 received a placebo, and 98 patients received prochlorperazine. One 
study found prochlorperazine to be the better antiemetic at treating nausea and vomiting, one 
study found metoclopramide to be better, and three studies found that the prophylactic use of 
metoclopramide cannot be justified.  
Conclusion 
There is no consensus on the superiority of metoclopramide or prochlorperazine to treat 
uncomplicated nausea and vomiting in the emergency care setting. There is a paucity of 
research available and further studies needs to be done, particularly in the prehospital arena. 
 
Abstract word count 267 
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Introduction 
Nausea and vomiting (N&V) are a common and distressing complaints that results in patients 
seeking emergency medical treatment[4, 8]. Nausea is a subjective sensation[1] and vomiting 
is the forceful expulsion of gastric contents through the mouth[10]. The nauseas patient gets 
an urge to vomit, associated with increased salivary secretions, sweating and vasomotor 
disturbances[10]. It is often thought that nausea and vomiting always coexist, but this is not 
always the case[1]. There are situations where a nauseas does not vomit, or a patient 
suddenly vomits without being nauseas[1].  
Anxiety, age, gender, alcohol consumption, ethnicity, opioid administration are some of the 
identifiable risk factors associated with nausea and vomiting[3, 10, 11]. Alcohol has been 
shown to be a major contributor to nausea and vomiting in a healthy population[3]. Motion 
sickness has been associated with patients becoming nauseas[17]. Patients travelling in the 
back of an ambulance can become nauseas and the administration of an antiemetic becomes 
necessary to safely manage these patients[18]. In the prehospital setting antiemetics are 
administered to relieve nausea and vomiting that potentially resulted from driving conditions, 
patients being placed in a claustrophobic environment,  patient positioning in the ambulance, 
or because an opioid analgesic might have been administered[8]. Should the patient vomit in 
the back of an ambulance that patient is exposed to a higher risk of aspiration and airway 
compromise[42, 43]. The emergency care practitioner must be able to manage these 
conditions, to safely manage these patients  
In South Africa emergency medical services (EMS) practitioners are qualified at basic, 
intermediate and advanced life support level. The basic life support practitioner having a very 
limited scope of practice focused at maintaining basic life functions through to the advanced 
life support (ALS) practitioner with a broader scope of practice[7].The current scope of practice 
only allows  the use of metoclopramide to treat nausea and vomiting in the prehospital setting, 
administered only by ALS[7]. In Australia and America paramedics have a wider selection of 
antiemetics, such as ondansetron, metoclopramide, prochlorperazine,  and diphenhydramine 
that they can administer, unlike in South Africa where the ALS paramedic only has 
metoclopramide available to them[44, 45].  
Metoclopramide and prochlorperazine have both been long established antiemetics[24, 28]. 
Both these drugs are readily available in South Africa and are easy to administer in the 
emergency setting[28]  The scoping review aims to map the available literature on 
metoclopramide and prochlorperazine use in the emergency setting to treat nausea and 
vomiting. 
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Methods 
A scoping study, as explained by Arksey and O´Malley[46], is undertaken to view the range, 
depth and extent of research on a particular subject, to ascertain the value of conducting a full 
systematic review on a topic, to review and share the available literature on a subject, to 
identify research gaps in the existing literature on a topic[46]. For the purpose of this study, 
the scoping review definition by Daudt  HML, van Mossel C and Scott SJ[47] will be used. 
They define a scoping review as a form of research synthesis with the objective to “map the 
literature on a particular topic or research area and provide an opportunity to identify key 
concepts; gaps in the research; and types and sources of evidence to inform practice, policy 
making and research”[47]. This review, being a stand-alone project, was guided by Arksey 
and O’Malley’s six stage framework[46]; (1) identifying the research question, (2) searching 
the relevant studies, (3) selection of the relevant studies, (4) charting the data, (5) collating 
the results, and (6) summarising and reporting the results[46] 
 
Search strategy 
A broad literature search was done, to achieve a comprehensive scope of the literature 
available. The following online databases Pubmed, Medline, Embase Cochrane databases, 
CINAHL, Web of Science, TRIP and EBSCO host were searched. Identifiable search terms 
such as “nausea”, “vomiting”, “emergency care setting”, “prehospital”, “emergency medical 
services”, “metoclopramide”, “prochlorperazine”, “motion-sicknesses was used to search for 
relevant literature. 
Articles chosen for this review were subjected to the inclusion and exclusion criteria as listed 
in Table 1.   
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Table One. Inclusion and Exclusion criteria 
 Inclusion Exclusion 
Source Published peer reviewed journals Not sourced from a peer reviewed 
journal 
Publication  
date 
Between January 1989 up to and 
including December 2018 
Any research prior to 1989 
Language English printed articles Any other language other than English 
Study type RCT, case studies, observational 
studies, cross-sectional surveys, 
case -control studies 
Case reports, literature reviews and 
secondary research articles, that 
reviewed primary studies already 
included in this review. 
 Study 
intervention 
Use of metoclopramide or 
prochlorperazine toi treat nausea 
and vomiting  
Use of metoclopramide and/or 
prochlorperazine to treat 
illnesses/symptoms outside of nausea 
and vomiting 
Study 
Setting 
Emergency centre  
Prehospital research 
Theatre setting, any other environment 
other than an emergency department or 
prehospital emergency setting 
RCT Randomised control trial 
 
Article Selection and Extraction 
The initial search for articles identified 43 121 potential articles that was screened by title for 
relevance and inclusion criteria. Articles not in English print (1031) were removed. After 
abstract screening and reviewing 33 277 articles were removed. Patents, case reports, 
reference reports, secondary research articles and duplicates were also removed.   Identified 
articles were reviewed against the inclusion and exclusion criteria in table one. The remaining 
articles were reviewed by a second author (IH) to verify eligibility for inclusion, with any 
disagreements resolved by mutual agreement, Figure 1. From the article and literature search 
only 11 randomised control, trials (RCT) were found that evaluated metoclopramide and/or 
prochlorperazine in an emergency setting and were eligible for inclusion.  
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Fig.1 Selection of articles for the review 
43 121 potential articles 
• Scopus 8749 
• Medline and Pubmed 8574 
• Web of Science 6940 
• Gale, Wiley 6029  
• ProQuest 10870 
• Elsevier 269 
• SpringerLink 1690 
Exclude non-
English 
based articles 
• 1031 
42 090 Potential Articles  
12 248 possible articles 
 
 
Exclusion criteria 
• Migraine 200 
• Pain 130 
• Analgesic 100 
• Pain Management 96 
• Palliative care 60 
• Headache 626 
• Postoperative nausea and 
vomiting 1 515 
• Postoperative 
complication 280 
• Surgery 2 635 
• Chemotherapy 800 
• Antineoplastic agent 493 
 
 
 
 
Inclusion Criteria 
• Emergency 
Medical Services 
• Emergency 
Department 
• Prehospital care 
Subject search Criteria 
• Metoclopramide 
• Nausea and 
Vomiting 
• Antiemetic 
• Prochlorperazine 
8813 articles for review  
8802 Articles removed 
• 7817 reference entries 
newspaper articles  
• 981 text resources and 
patents 
• 4 secondary studies 
11 Articles 
Initial Search terms 
• metoclopramide, prochlorperazine 
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Results 
Eleven studies were selected for this review[30, 31, 49, 33–39, 48] (Table 2). All 11 studies 
were RCTs. All of the studies were peer-reviewed journal articles. Ten of the studies were 
conducted in an EC[30, 31, 33–35, 37–39, 48, 49] and one in the prehospital setting[36]. Six 
of the studies originated from America[33–36, 38, 39], three studies originated from 
Australia[30, 31, 37] one from the United Kingdom[49] and one from New Zealand[48]. Nine 
studies evaluated metoclopramide[30, 31, 33–37, 48, 49] and three studies evaluated 
prochlorperazine[33, 38, 39]. All selected studies were published between 1999 to 2014.  
NAUSEA ASSESSMENT 
All studies reported on the presence of nausea. Eight studies reported on change in nausea  
post administration of an antiemetic[30, 33–39] and three studies just stated whether the 
patient was nauseas or not[31, 48, 49] (Table 2). Nausea can be assessed using the visual 
analogue scale (VAS) or discrete scale (DS) [20, 21]. Seven studies utilised VAS[33–39], Two 
studies utilised a DS[30, 31], one study required the patient to state whether they are nauseas 
or not nauseas[49].  
ANTIEMETIC EVALUATION  
Five studies evaluated the effectiveness of metoclopramide for the treatment of nausea and 
vomiting in the EC[31, 33–35, 37]. In the studies by  Egerton-Warburton et al[37], Braude et 
al[33], and Barrett et al[35] the patient received 10mg metoclopramide. Chae et al[34] does 
not mention the dosage administered to the patient and in the study by Cham et al[31] one 
study group received 10mg metoclopramide and the second study group received 0.4mg/kg 
metoclopramide. One study evaluated the effectiveness of metoclopramide in the prehospital 
setting[36]. In the study by Rubio et al[36] patients received 20mg metoclopramide. Three 
studies evaluated the effectiveness of metoclopramide when administered prophylactically[30, 
48, 49]. In the study by Lambie et al[48] administered 10mg metoclopramide prophylactically 
prior to the patient receiving morphine, Talbot-Stern et al[30] administered 10mg 
metoclopramide immediately after morphine or pethidine was administered, Bradshaw and 
Sen[49] administered 10mg metoclopramide before morphine was administered. Three 
studies evaluated prochlorperazine in the EC setting[33, 38, 39]. In the studies by Ernst et 
al[38], Braude et al[33] and Patka et al[39] patients received 10 mg prochlorperazine  
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ADVERSE EFFECTS 
Adverse effects was reported in nine studies[30, 31, 33–39]. Akathisia was reported in four 
studies[34, 37–39], sedation and drowsiness reported in five studies[33–35, 38, 39], dystonic 
reactions and vertigo reported in one study[30] 
RESCUE MEDICATION 
The use of rescue medication (the administration of an additional antiemetic to treat nausea 
and vomiting) in all the studies found. Only three studies documented what the rescue drug 
was[36, 48, 49]. Seven studies mention that rescue medication was needed and administered 
but does report what medication was used[30, 33–35, 37–39] 
STUDY CONCLUSIONS 
Lambie  et al[48], Talbot-Stern et al[30] and  Bradshaw and Sen[49] concluded that the  
prophylactic administration of metoclopramide does not reduce the incidence of nausea and 
vomiting. Egerton-Warburton et al[37] concluded that there the reduction in the severity  of 
nausea was the same in all  study groups.  Cham et al[31] concluded that the effectiveness of 
metoclopramide in treating N&V is the same whether the patient receives 10mg 
metoclopramide or 0.4mg/kg metoclopramide. Braude et al[33] found no difference between  
metoclopramide and prochlorperazine in treating N&V,  and found droperidol to be more 
effective than both metoclopramide and prochlorperazine. Chae et al[34] concluded that 
tropisetron  was associated with significantly lower vomiting rates than metoclopramide.  
Barret et al[35] concluded that there was no difference between metoclopramide and 
ondansetron in reducing nausea in the EC patients[35]. Rubio et al[36] found metoclopramide 
to be better at treating motion sickness than diphenhydramine. Ernst et al[38] found 
prochlorperazine to work significantly better than promethazine in relieving nausea and 
vomiting. Patka et al[39] concluded that ondansetron and prochlorperazine were  the same at 
treating N&V in the EC.
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Table 2 Overview of articles 
 
 
 
Author Year Study Type and 
setting 
Sample size 
 Drug studied Scale used Rescue  
Drug 
Adverse effects Study Conclusion 
1 Lambie 1999 RCT 
EC 
New Zealand 
N=214 pts 
Metoclopramide vs 
placebo 
Pt was 
asked if 
they were 
nauseas or 
not 
cyclizine None reported Routine administration of 
metoclopramide is not 
justified 
2 Talbot-
Stern 
2000 RCT 
EC 
Australia 
N=122 pts 
Metoclopramide vs 
placebo 
Pt had to 
rate nausea 
Mild 
moderate 
Or severe 
 Dystonic 
reaction 
Vertigo 
Dizziness 
Drowsiness 
Restlessness 
 
Metoclopramide should not be 
given prophylactically to 
patients that have received IV 
analgesia 
3 Ernst 2000 RCT 
EC 
America 
N=84 pts 
Prochlorperazine 
vs promethazine 
100mm 
VAS 
 Akathisia 
Drowsiness 
Prochlorperazine is more 
effective at treating 
uncomplicated nausea and 
vomiting 
4 Cham 2004 Prospective 
RCT 
Metoclopramide 
intermediate dosing 
Verbal 
rating Scale 
 Swollen tongue 
Oculogyric crisis 
No difference between the 
dosing regimens of 
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EC 
Australia 
N=58 pts 
vs metoclopramide 
standard dosing 
metoclopramide in treating 
nausea and vomiting 
5 Bradshaw 2006 RCT 
EC 
United Kingdom 
N=259 pts 
Metoclopramide vs 
placebo 
Pt had to 
say if they 
felt sick or 
not 
cyclizine None reported Routine prophylactic 
administration of 
metoclopramide to patients 
that have received IV 
morphine is not justified 
6 Braude 2006 RCT  
EC 
America 
N=100 pts 
Droperidol vs 
metoclopramide vs 
prochlorperazine vs 
placebo 
100mm 
VAS 
 Anxiety 
Sedation 
No difference between 
metoclopramide and 
prochlorperazine when 
compared to the placebo to 
treat nausea. Droperidol does 
have a higher risk of akathisia 
but is more effective in 
treating nausea and vomiting 
7 Chae 2011 RCT 
EC 
America 
N=100 pts 
Tropisetron vs 
metoclopramide 
100mm 
VAS 
 Akathisia 
Drowsiness 
Headache 
 
Tropisetron proved to be more 
effective at treating nausea 
and vomiting when compared 
to metoclopramide 
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8 Barret 2011 RCT 
EC 
America 
N=180 pts 
Ondansetron vs 
metoclopramide vs 
promethazine vs 
placebo 
100mm 
VAS 
 Akathisia 
Sedation 
No difference between 
ondansetron promethazine 
and metoclopramide in 
reducing nausea 
9 Rubio 2011 RCT 
Prehospital 
America Sierra 
Nevada 
N=22 pts 
Metoclopramide vs 
Diphenhydramine 
vs 
Placebo 
100mm 
VAS 
metoclop
ramide 
Dy mouth Metoclopramide showed 
superiority in treating motion 
sickness when compared to 
diphenhydramine and a 
placebo 
10 Patka 2011 Prospective 
RCT 
EC 
America 
N=64 pt 
Ondansetron vs 
prochlorperazine 
 
100mm 
VAS 
 Akathisia 
Sedation 
Prochlorperazine does seem 
to be more effective at 
managing nausea 
 
11 Egerton-
Warburton 
2014 RCT 
EC 
Australia 
N=258 pts 
Ondansetron vs 
Metoclopramide vs 
Saline 
 
100mm 
VAS 
 Akathisia 
Restlessness 
Sweatiness 
Muscle 
Twitching 
Dizziness 
No difference in either 
Ondansetron or 
metoclopramide over saline in 
treating nausea and vomiting 
RCT: Randomised Control Trial; EC: Emergency Centre; Pts: Patients; VAS: Visual Analogue Scale 
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 Discussion 
 
The use of anti-emetics to treat nausea and vomiting is common practice in the prehospital 
setting[8]. This scoping review evaluated the available literature on metoclopramide and 
prochlorperazine use in treating nausea and vomiting in the emergency care patient. Even 
though a broad-based literature search was done only 11 articles were found that evaluated 
metoclopramide and or prochlorperazine use in the emergency setting to treat nausea and 
vomiting[18-28]. The limited available research for this review, is surprising, considering the 
fact that nausea and vomiting are frequent symptoms in patients presenting to the emergency 
centre[25].  
A systematic review done in 2011 by Simpson et al[50], was conducted on prophylactic 
metoclopramide in the emergency setting, and identified only three studies[50]. Simpson et 
al[50] concluded in their review that the prophylactic administration on metoclopramide could 
not be justified[50]. The authors acknowledged that their analysis would be underpowered and 
they would have to enrol approximately 2000 patients to be able to achieve 80% power and 
statistical significance[50]. Following the systematic review by Simpson et al[50], in 2014 a 
Cochrane review was conducted by Fury et al[25], on drugs to treat nausea and vomiting in 
the EC[25]. and identified only eight studies[25]. 
The authors of this review also found that there is limited research available on antiemetic use 
in the emergency setting. Consistent with the findings of this scoping review, Fury et al[25] 
also found no convincing evidence supporting the superiority of any particular antiemetic over 
another[25]. In 2018 Verma et al[8] conducted a systematic review on antiemetic safety and 
efficacy in the prehospital setting[8]. Seven articles were found to be eligible for the review by 
Verma et al[8]. This review also found reporting be variable across the selected studies[8]. 
The administration of any medication comes with side effects[51]. Reporting on adverse 
effects of the antiemetics administered varied across the studies found for this review.  As 
noted above, not all the studies found reported on adverse drug reactions to metoclopramide 
and or prochlorperazine. Akathisia, drowsiness and sedation were the most commonly 
reported adverse effects, and it is concerning that some studies found did not report on any 
adverse effects[25, 48, 49] 
What is apparent from this scoping review is that metoclopramide is widely used to treat 
nausea and vomiting in the emergency care setting. Metoclopramide was evaluated in nine 
studies. In South Africa and other resource constrained countries, the low cost of 
metoclopramide, will most certainly influence its availability and the choice of antiemetic used 
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to treat nausea and vomiting. Metoclopramide is cheaper than prochlorperazine and more 
readily available [52].  
From the evidence found in this review, neither metoclopramide nor prochlorperazine showed 
any superiority in treating nausea and vomiting in the emergency setting. Further to that the 
evidence found in this review does not support the prophylactic use of metoclopramide in the 
prehospital setting when a patient receives an opioid analgesic. This is similar to the findings 
by Meltzer et al[53], whose  take home message was that the only antiemetic that had a 
statistically significant decrease in VAS score at 30 minutes was droperidol[53]. 
Metoclopramide was also evaluated in a study by Henzi et al[54]  who analysed data on more 
than 6000 adults and children in the postoperative setting. Henzi et al[54] concluded that 
metoclopramide does not show any clinically relevant antiemetic effect[54].  
Conclusion 
In conclusion there is no consensus on the superiority of any one drug to treat nausea and 
vomiting, yet it is important to effectively treat nausea and vomiting in the emergency care 
setting. The use of metoclopramide or prochlorperazine to treat nausea and vomiting in the 
emergency care setting does expose the patient to a significant risk of harm from the adverse 
effects of the drugs, and needs to be carefully considered, especially in the light of the 
overwhelming evidence that neither drugs are particularly effective in this role. Further 
research needs to be conducted on the safety and efficacy of metoclopramide and 
prochlorperazine to treat nausea and vomiting in the emergency setting, as well as to consider 
other agents which have shown promise elsewhere. 
Strengths and Limitations 
This is the first scoping review attempting to map out the available literature on 
metoclopramide and prochlorperazine use in the treatment of nausea and vomiting in the 
emergency setting. This review has highlighted the need for further research on antiemetic 
use in the South African emergency care setting. 
The homogeneity of the evidence found for this review was not established; and only English-
language research was included which may subject the results to language and publication 
bias. The paucity of research available on the topic also limited this research 
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Appendix One 
 
Breakdown of studies selected for review: 
  
1. A randomized, placebo-controlled trial of ondansetron 
metoclopramide, and promethazine in adults[35] 
Author Barret 
Study method Randomised Control Trial (RCT) placebo controlled Double blind 
Control was the placebo arm 
Study year 2011 
Study setting Emergency Department 
Vanderbilt University Medical Centre Nashville Tennessee 
Study Aim Whether Ondansetron is superior to metoclopramide, promethazine or 
saline placebo in reducing nausea in patients in the emergency 
department 
Population 180 Consenting adults 18 years or older  
163 completed the study 
Pt’s presented to the emergency department complaining of nausea 
and vomiting, requiring intravenous antiemetics to be administered 
Pt. Demographics Median age 32 Interquartile range 23-47 
68% females 
Method to assess 
nausea 
100 mm Visual analogue scale (VAS) 
Drug protocol Pts received either  
10mg metoclopramide 4mg ondansetron 12.5mg promethazine  
2ml saline  
All drugs diluted to a 2ml volume  
Nausea Relief A mean reduction 30 minutes after medication given VAS  
Ondansetron -22 (-32 to -15) 
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Metoclopramide -30 (-38 to -25.5)  
Promethazine -24 (-40 to-21) 
Saline -16 (-25 to -3) 
CI 95% 
Adverse effects Akathisia  
Metoclopramide N=43 
9 mild 1 moderate 1 severe 
Ondansetron N=36 
3 mild 1 moderate 1 severe 
Sedation 
Metoclopramide 
10 mild 8 moderate 3 severe 
Ondansetron 
10 mild 4 moderate 2 severe 
Rescue Medication 9 pts that got metoclopramide received rescue medication 
23 pts in the placebo arm and  
19 pts in the ondansetron arm  
Outcome of this study No difference between ondansetron promethazine and 
metoclopramide in reducing nausea  
 
2. Antiemetics in the ED: a randomised controlled trial comparing 3 
common agents [33] 
Author Braude 
Study method RCT placebo double blind controlled trial 
Control was the placebo arm 
Study setting Emergency Department 
Fresno California 
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Study year 2006 
Study Aim To prospectively compare the efficacy of droperidol, metoclopramide, 
prochlorperazine with each other and a saline placebo in patients 
complaining of moderate to severe nausea  
Population Adult patients presenting with nausea to the emergency department 
100 patients enrolled 
Pt’s were between 18 to 65 years complaining of nausea and vomiting 
with a baseline nausea rating of at least 40mm on the 100mm VAS  
Pt. Demographics Total of 97 patients 
42 males 55 females 
Method to assess 
nausea 
100mm VAS 
Drug protocol 2ml prefilled syringes 
1.25mg droperidol, 10mg metoclopramide,10mg prochlorperazine 
2ml saline 
Nausea Relief Mean ± standard deviation 
Droperidol -54.5 ± 18.4 
Metoclopramide -40.2 ± 23.8 
Prochlorperazine -40.5 ± 24.1 
Saline -38.7 ± 21.1 
Adverse effects [mean ± SD] 
Anxiety  
Droperidol -23.8 ± 25.4 
Metoclopramide -25.4 ± 24.3 
Prochlorperazine -21.9 ± 38.0 
Saline -31.7 ± 31.6 
Sedation 
Droperidol 13.5 ± 32.2 
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Metoclopramide 0.4 ± 30.1 
Prochlorperazine 5.1 ± 26.5 
Saline -4.8 ± 25.0  
Droperidol caused more anxiety or restlessness that was self-reported 
by the patients 
Rescue Medication Droperidol 1 patient 
Metoclopramide 1 patient 
Prochlorperazine 6 patients 
Saline 4 patients 
Outcome of study Metoclopramide and prochlorperazine were not more effective than 
saline in treating nausea. 
Droperidol when administered intravenously does have a higher risk 
of akathisia, but was more effective than metoclopramide and 
prochlorperazine in treating nausea 
 
3. Randomised Control Trial of Ondansetron vs. Prochlorperazine in 
Adults in the Emergency Department[39] 
Author John Patka 
 
Study method Prospective RCT, Double blind active controlled 
Study setting Emergency Department 
South Regional Hospital Riverdale 
Study year 2011 
Study Aim To compare the effectiveness of ondansetron and prochlorperazine in 
the treatment of nausea in adult emergency department patients 
Population Adult patients admitted to the emergency department complaining of 
nausea and vomiting. Pt’s were older than 18 years 
Pt. Demographics Prochlorperazine group 
N=32    17 females  
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Ondansetron group 
N=32     18 females  
Method to assess 
nausea 
100mm VAS 
Drug protocol Patients received either 
4mg ondansetron intravenously or 10mg prochlorperazine 
intravenously 
Nausea Relief Mean ± SD 
0 minutes  
Ondansetron 72.4 ± 25.6 
Prochlorperazine 78.6 ± 28.5 
0 to 30 minutes 
Ondansetron 50.4 ± 33.0 
Prochlorperazine 47.5 ± 33.3 
 
31 to 60 minutes 
Ondansetron 43.7 ± 33.5 
Prochlorperazine 24.9 ± 31.8  
61 to 120 minutes 
Ondansetron 34.3 ± 31.7 
Prochlorperazine 16.8 ± 29.1  
Adverse effects Increased sedation 
Ondansetron 5 (16%) 
Prochlorperazine 7 (22%) 
Akathisia 
Ondansetron 1 (3%) 
Prochlorperazine 3 (9%) 
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Rescue Medication Ondansetron 5 patients 
Prochlorperazine 1 patient 
Outcome of study Prochlorperazine does seem to better at managing nausea when 
compared to ondansetron. There is very little difference between the 
two drugs when used to treat vomiting 
 
 
4. Prochlorperazine Versus Promethazine for Uncomplicated Nausea 
and Vomiting in the Emergency Department: A Randomised Double-
Blind Clinical Trial[38] 
Author Amy A Ernst 
Study method RCT Double blind study 
Study setting Emergency Department 
Vanderbilt University hospital in Nashville Tennessee  
University of California-Davis Sacramento California 
Study year 2000 
Study Aim To compare prochlorperazine and promethazine to treat 
uncomplicated nausea and vomiting in the emergency department. 
The null hypothesis was that prochlorperazine and promethazine are 
equally effective at relieving nausea and vomiting symptoms 
Population Pt’s that were 18 years or older that came to the emergency 
department with uncomplicated gastritis or gastroenteritis 
Pt. Demographics Prochlorperazine group 
N=42 14 males 28 females 
Promethazine group 
N=42 11 males 31 females 
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Method to assess 
nausea 
100mm visual analogue scale 
Drug protocol Pts received either  
10mg prochlorperazine diluted in 9ml saline or 25mg promethazine 
diluted in 9ml saline 
Nausea Relief Median 
Baseline 
Prochlorperazine 6.5 
Promethazine 7.3 
30 minutes 
Prochlorperazine  
Median 2 
Median change from base line 4.5 
Promethazine  
Median 4.6 
Median change from base line 2.7 
60 minutes 
Prochlorperazine 
Median 0.45 
Median change from 30 min VAS 1.55 
Promethazine  
Median 2.6 
Median change from 30 min VAS 2.0  
Adverse effects Prochlorperazine 
Drowsiness 16 pts 
Akathisias 6 pts 
Promethazine  
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Drowsiness 30 pts 
Akathisias 6 pts 
Rescue Medication Prochlorperazine 4 pts 
Promethazine 13 pts 
Outcome of study Prochlorperazine proved to be more effective than promethazine in 
treating uncomplicated nausea and vomiting. The risk of akathisia is 
the same for both drugs, and promethazine does cause more 
drowsiness in the patients 
 
 
5. Antiemetic Use for Nausea and Vomiting in Adult Emergency 
Department Patients:  Randomised Controlled Trial Comparing 
Ondansetron, Metoclopramide, and Placebo[37] 
Author Diana Egerton-Warburton 
Study method Prospective double-blind RCT 
Placebo controlled 
Study setting Emergency Department 
Monash Medical Centre and Dandenong Hospital 
Australia 
Study year 2014 
Study Aim The study compared the efficacy of ondansetron and metoclopramide 
with a placebo in treating uncomplicated nausea and vomiting  
Population Pts were 18 years or older and presented to the emergency 
department complaining of nausea and vomiting.  
 
Pt. Demographics Ondansetron 
N=87    Median age 42 Females 56 
Metoclopramide 
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N=88     Median age 42 Females 58 
Saline placebo 
N=83       Median age 42 Females 55 
Method to assess 
nausea 
100mm VAS 
Drug protocol Metoclopramide 10mg/2ml drawn up in 2ml syringe.  2*2ml syringes 
filled with 2ml metoclopramide were sealed in a pack. Total dosage 
20mg 
Ondansetron 4mg/2ml drawn up in a 2ml syringe. 1*2ml syringe filled 
with 0.9%saline and another 2ml syringe with ondansetron were 
sealed in another pack 
Placebo 2*2ml syringes filled with 0.9% saline sealed in a third pack 
Nausea Relief Median  
Initial rating  
Ondansetron 52mm 
Metoclopramide 50mm 
Placebo 52mm 
Post treatment 
Ondansetron 19mm 
Metoclopramide 18mm 
Placebo 27mm  
Change in VAS 
Ondansetron 27mm (95% CI 22 to 33mm) 
Metoclopramide 28mm (95% CI 22 to 34mm) 
Placebo 23mm (95% CI 16 to 30mm)   
 
Adverse effects Metoclopramide 
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Akathisia 2 Restlessness 2 Sweatiness 1 Muscle twitching 1 
Ondansetron 
Dizziness 1 Stinging at injection site 1 
Placebo 
Shaking/restlessness 1 
Rescue Medication Ondansetron 29 pts (34.5%) (95% CI 25% to 45%) 
Metoclopramide 15 pts (17.9%) (95% CI 10.8% to 27.2%) 
Placebo 29 pts (36.3%) (95% CI 26.3% to 47.2%) 
Outcome of study Reduction in nausea and vomiting were similar in all three drugs. The 
use of antiemetic drugs did not show a significant benefit over the 
placebo in treating nausea and vomiting 
 
6. Intermediate dose metoclopramide is not more effective than 
standard dose metoclopramide for patients who present to the 
emergency department with nausea and vomiting: A pilot study [31] 
Author Swee Cham 
Mary Basire 
Study method Prospective RCT 
Single blind study 
Study setting Emergency Department 
Western Hospital in Footscray and Northern Hospital in Epping 
Victoria Australia 
Study year 2004 
Study Aim To ascertain if intermediate dosing of metoclopramide is better than 
standard dosing for the patient that comes to the emergency 
department complaining of nausea and vomiting 
Population Patients were 18 years and/or older and required treatment for nausea 
and vomiting 
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Pt. Demographics 10mg metoclopramide 
N=34       Age median 34 Males = 9 
0.4mg/kg metoclopramide 
N =24       Age median 42 Males = 8 
Method to assess 
nausea 
A verbal rating scale 0 to 10 
Drug protocol Patients either received 
10mg metoclopramide 
0.4mg/kg metoclopramide maximum dose -weight 80kg (32mg) 
Nausea Relief Median 
Nausea reduction 
4 pts in the 10mg group (95% CI 3 – 5) 
5 pts in the 0.4mg/kg group (95% CI 4 – 6) 
Adverse effects 2 pts in the 0.4mg/kg group 
1 oculogyric crisis 1 Swollen tongue 
Rescue Medication 10mg group 5 pts 
0.4mg/kg 3 pts 
Outcome of study There is no difference between standard dose 10mg metoclopramide 
and 0.4mg/kg in treating nausea and vomiting in the emergency 
department patient.  
 
7. Prophylactic Metoclopramide is Unnecessary With Intravenous 
Analgesia in the ED[30] 
Author Janet Talbot-Stern 
Richard Paoloni 
Study method RCT double blinded placebo-controlled trial 
Study setting Emergency department 
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Royal Prince Alfred Hospital Sydney Australia 
Study year 2000 
Study Aim To assess the effect of metoclopramide on the incidence of nausea 
and vomiting after the patient received morphine or pethidine 
analgesia 
Population Pts that presented to the emergency department in acute pain 
requiring intravenous morphine and pethidine. Pts were 16 years or 
older 
Pt. Demographics Metoclopramide 
N=63    Males= 48 (75%) Mean age= 41 Age range 17-83 
Placebo 
N=59      Males= 41 (68%) Mean age= 38 Age range 16-86 
Method to assess 
nausea 
Patients had to rate their nausea as mild, moderate, or severe. Author 
does not mention if the VAS was utilised   
Drug protocol An equal number of ampoules each containing a volume of 2ml of 
either normal saline or metoclopramide (10mg/2ml) 
Nausea Relief Metoclopramide  
N=63 
30 minutes= 3.2% 
60 minutes= 4.8% 
Placebo 
N=59 
30 minutes= 6.8% 
60 minutes= 3.4% 
Adverse effects 7.9% of the pts that received metoclopramide reported adverse effect 
not related to nausea and vomiting. 
The reported side effects were, dystonic reaction, vertigo and 
dizziness, drowsiness and restlessness 
Rescue Medication No patient required rescue medication  
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Outcome of study Metoclopramide should not be given prophylactically routinely to 
patients that have received IV analgesia. The severity and the 
frequency of side effects cannot be ignored 
 
 
8. Use of a prophylactic antiemetic with morphine in acute pain: 
randomised control trial[32]  
Author M Bradshaw 
A Sen 
Study method Prospective RCT double blind placebo-controlled study 
Study setting Emergency Department  
Wrexham Maelor Hospital United Kingdom 
Study year 2006 
Study Aim To compare the occurrence of nausea and vomiting in patients treated 
with morphine for acute pain that have received either prophylactic 
metoclopramide or placebo saline IVI 
Population Patients over the age of 12 years that came to the emergency 
department with any acute painful condition that required IV morphine 
to be administered  
 
Pt. Demographics Metoclopramide 
N=123      Median age 53 Males= 54 
Placebo 
N= 136        Median age= 52.5 Males= 65 
Method to assess 
nausea 
Patients were asked if they were feeling sick, or if they vomited. The 
answers had to be either Yes/No. 
Drug protocol Syringes were prefilled with either 2ml normal saline or 2ml 10mg/2ml 
metoclopramide. Syringes were numbered and selected at random to 
be administered to the patient 
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Nausea Relief Metoclopramide  
2 patients vomited 
Saline 
5 patients vomited 
Adverse effects Not reported on in the study 
Rescue Medication If any patient got nauseas and/or vomited they were given 50mg 
cyclizine  
Outcome of study Routine use of metoclopramide prophylactically to treat nausea in 
patients that were to receive IV morphine was not justifiable   
 
 
9. The role of prophylactic anti-emetic therapy in emergency 
department patients receiving intravenous morphine for 
musculoskeletal trauma[48] 
Author Bruce Lambie  
Study method Double blind placebo-controlled RCT 
Study setting Emergency Department 
Dunedin Hospital New Zealand 
Study year 1999 
Study Aim To determine if the routine administration of IV metoclopramide will be 
beneficial to the patient that has received IV morphine for 
musculoskeletal trauma  
Population Any patient older than 16 years that presented to the emergency 
department requiring IV morphine for musculoskeletal trauma 
Pt. Demographics Metoclopramide 
N=111       Mean age=46.5 Males=55 
Placebo 
N=103      Mean age=48 Males=53 
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Method to assess 
nausea 
Patients were asked if they were nauseas and/or vomited either by 
personal interview or by telephonic interview if the patient was 
discharged from the emergency department 
Drug protocol Syringes were independently prepared in batches of twenty and coded 
by number. Syringes either contained 2ml normal saline or 2ml 10mg 
metoclopramide 
Nausea Relief Metoclopramide  
No patients experienced severe nausea 
Placebo  
2 patients experienced severe nausea 
Adverse effects not reported on in this study 
Rescue Medication 2 patients in the metoclopramide group and one patient in the placebo 
received cyclizine  
Outcome of study Routine administration of metoclopramide to reduce vomiting when a 
patient is to receive IV morphine is not justified 
 
 
10. Motion Sickness: Comparison of  Metoclopramide and 
Diphenhydramine to Placebo[36] 
Author Stephanie Rubio  
Study method Prospective double-blind placebo-controlled RCT 
Study setting Prehospital environment 
Sierra Nevada, Fresno Country 
Study year 2011 
Study Aim To evaluate the efficacy of metoclopramide or diphenhydramine to 
relieve symptoms of motion sickness in patients being transported by 
an ambulance in a mountainous setting   
Population Any patient adult patient between 18 and 65 years old that required 
ambulance transportation in the mountainous areas of Fresno County 
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Pt. Demographics Metoclopramide 
N=8                  Mean age=34.5           Males= 5        Females=3 
Diphenhydramine 
N=7                  Mean age 44.6            Males= 5        Females=2 
Placebo 
N=7                  Mean age=43.7            Males= 3        Females=4 
Method to assess 
nausea 
100mm Visual analogue scale 
Drug protocol The night paramedic coming off night shift would draw up the 
medication and label the medication with a randomly assigned number 
Nausea Relief Metoclopramide  
5 min 19.1 (95%CI =7.9-30.3)   10 min 11.0 (95%CI= 4.7-10.7) 
Placebo  
5 min 53.1 (95%CI= 37.1-69.1) 10 min 54.1 (95%CI= 40.1-68.1) 
Diphenhydramine 
5 min 54.9 (95%CI= 40.4-69.4) 10 min 53.9 (95%CI= 39.4-68.4) 
Adverse effects One patient in the placebo group reported a dry mouth. No dystonic 
reactions reported. 
Rescue Medication 12 patients requested a rescue dose of metoclopramide at 15 minutes. 
6 pts were in the placebo group, 5 in the diphenhydramine group and 
1 in the metoclopramide group  
Outcome of study Use of metoclopramide to reduce motion sickness during ambulance 
transportation is superior to diphenhydramine and a placebo 
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11. Tropisetron versus metoclopramide for the treatment of nausea and 
vomiting in the emergency department: A randomised, double-
blinded, clinical trial[34] 
Author John Chae  
Study method Double blind placebo-controlled RCT 
Study setting Emergency department  
Austin Hospital Melbourne Australia 
Study year 2011 
Study Aim To compare the efficacy of tropisetron and metoclopramide in treating 
undifferentiated nausea and vomiting in emergency department 
patients  
Population Any patient older than 18 years that presented to the emergency 
department with nausea and vomiting that required drug treatment 
Pt. Demographics Metoclopramide 
N=50     Mean age=56.7 Males= 21 
Tropisetron 
N=50    Mean age=53.3 Males=21 
Method to assess 
nausea 
100mm VAS 
Drug protocol Patients were given either 5mg tropisetron or 10mg metoclopramide 
depending on their allocation 
Nausea Relief Metoclopramide  
 The decrease in nausea from baseline was 37mm 
Tropisetron  
The decrease in nausea from baseline was 47.9mm 
Adverse effects Akathisia was reported on. Tropisetron showed lower mean akathisia 
scores and one patient in the metoclopramide arm required 
benztropine  
There was no difference in mean drowsiness 
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 Headaches were reported by 11 pts in the tropisetron group and 5 in 
the metoclopramide group 
Rescue Medication 13 patients in the metoclopramide group and 5 patients in the 
tropisetron group required a rescue anti-emetic 
Outcome of study Tropisetron was associated with a lower vomiting rate and shows 
promise as an alternative antiemetic  
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Appendix Two 
 
INTRODUCTION The African Journal of Emergency Medicine (AfJEM, ISSN: 2211-419X) is 
the official journal of the African Federation for Emergency Medicine. It is an international, 
peer-reviewed journal aimed in particular at supporting emergency care across Africa. 
AfJEM publishes original research, reviews, brief reports of scientific investigations, case 
reports as well as commentary and correspondence related to topics of scientific, ethical, 
social and economic importance to emergency care in Africa. Articles will be of direct 
importance to African emergency care but may have originated from elsewhere in the world.  
TYPES OF ARTICLES  
Original Article:  
Original studies of basic or clinical investigations in areas relevant to emergency medicine. 
Reference to the relevance of the research in a resource poor setting is essential and should 
be alluded to in the discussion section. References and a structured abstract (see 
Preparation below) are required. Maximum length: 3,000 words, 5 tables and/or figures, plus 
the abstract (300 words) and references (max 50).  
The checklists found on the following websites should be used to structure your manuscript 
(a copy of the checklist indicating which elements of the reporting format you adhered to, a 
signed conflict of interest form and Author statement form - see below- should be submitted 
with your manuscript): 
 a. For randomised control trials: http://www.consort-statement.org  
b. For cohort, case-control, and cross-sectional studies: http://www.strobe-statement.org/ 
 c. All other studies: http://www.equator-network.org/  
 
2. Review Articles:  
Extensive reviews of the literature on a narrow clinical topic. References must include, but 
need not be limited to, the past 3 years of the literature. A structured abstract is required 
(see Preparation below). Maximum length: 3,000 words, plus the abstract (max 300 words) 
and references (max 50). Please contact the editor in chief before you submit a review. 
The following reporting checklists should be used to structure your manuscript (a copy of the 
checklist indicating which elements of the reporting format you adhered to, a signed conflict 
of interest form and Author statement form - see below- should be submitted with your 
manuscript):  
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a. A Resourced-tiered review checklist is the standard reporting format for publication in 
AfJEM: http://www.afjem.com/resource-tiered-checklist.html  
b. If your topic does not lean itself towards a resourced tiered review consider alternative 
reporting checklists for systematic reviews and meta-analyses such as Prisma checklist 
(http://www.prisma-statement.org) or similar.  
 
Please check with the editor-in-chief before using a checklist other that the resources-tiered 
checklist.  
3. Case Reports: 
 Brief descriptions of a previously undocumented disease process, a unique unreported 
manifestation or treatment of a known disease process, or unique unreported complications 
of treatment regimens. Case reports should be structured as follow: Introduction, Case 
report and Discussion. It should not contain an exhaustive review of the literature. Consider 
consent for patient identifiable information (download from website). A structured abstract 
(see Preparation below) is required. Maximum length: 1,000 words, plus abstract (max 150 
words) and references (max 10), and 1 table or figure a copy of the checklist indicating 
which elements of the reporting format you adhered to, a signed conflict of interest form and 
Author statement form - see below should be submitted with your manuscript). Case reports 
listed for publication after 2015 are published online only and compiled within a virtual issue 
once a year.  
4. Practical Pearl (upload as Technical note): 
 Descriptions of novel approaches to provision of emergency care; and practical "tricks of the 
trade" describing aspects of emergency medicine management. An abstract is not required 
(enter: Not required, practical pearl when prompted). Maximum length: 800 words, 5 tables 
and/or figures and references (max 5). A manuscript template is available at 
http://www.afjem.com/#author and can be used for submission (a signed conflict of interest 
form- see below- should be submitted with your manuscript). Note that author details should 
be included in the manuscript. 
 5. Abbreviated paper (previously Brief Research Reports):  
Reports of preliminary data and findings or studies with small numbers demonstrating the 
need for further investigation. References and a structured abstract (see Preparation below) 
are required. Maximum length: 1,500 words, plus the abstract (max 300 words) and 
references (max 10) and 3 tables and/or figures. Checklists described for original research 
above should be used to structure your manuscript (a copy of the checklist indicating which 
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elements of the reporting format you adhered to, a signed conflict of interest form and Author 
statement form - see below- should be submitted with your manuscript)  
6. Commentary: Descriptions of clinical and nonclinical problems and solutions; descriptions 
of novel approaches to planning, management, or provision of emergency services; and 
practical " how-to" articles describing aspects of emergency medicine management (includes 
African country acute care profiles). A narrative abstract (see Preparation below) is required. 
Maximum length: 3,000 words, plus the abstract (max 300 words) and references (max 50). 
A signed conflict of interest form- see below- should be submitted with your manuscript. 
 7. Editorials (commissioned and including op-ed): Authoritative comments or opinions on 
major current problems of emergency physicians or on controversial matters with significant 
implications for emergency medicine; or, qualified, thorough analysis and criticism of articles 
appearing in AfJEM. Maximum length: 1,500 words plus references (max 5). An abstract is 
not required. A signed conflict of interest form- see below- should be submitted with your 
manuscript.  
8. Correspondence: Discussion, observations, opinions, corrections, and comments on 
topics appearing in AfJEM; very brief reports or other items of interest. Maximum length: 500 
words, plus references (max 5). An abstract is not required. Please enter: Not applicable, 
Correspondence when prompted to enter an abstract. Letters discussing an AfJEM article 
should be received within 6 weeks of the article's publication. The article must be included in 
the references. Authors of articles about which letters are received will be given the 
opportunity to reply, which will not be shared with the letter writer prior to publication. Letters 
of political or other topics unrelated to the science of medicine, as well as those containing 
personal criticisms, will not be published. A signed conflict of interest form see below- should 
be submitted with your manuscript 
 9. Erratum: Corrections on topics appearing in AfJEM. Maximum length: 300 words, plus 
references (max 5). An abstract is not required. Please enter: Not applicable, Erratum when 
prompted to enter an abstract. Letters discussing an AfJEM article should be received within 
6 weeks of the article's publication. The article must be included in the references. Authors 
of articles about which letters are received will be given the opportunity to reply, which will 
not be shared with the letter writer prior to publication. Letters of political or other topics 
unrelated to the science of medicine, as well as those containing personal criticisms, will not 
be published elsewhere including electronically in the same form, in English or in any other 
language, without the written consent of the copyright-holder. A signed conflict of interest 
form- see below- should be submitted with your manuscript.  
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Submission Our online submission system guides you stepwise through the process of 
entering your article details and uploading your files. The system converts your article files to 
a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are 
required to typeset your article for final publication. All correspondence, including notification 
of the Editor's decision and requests for revision, is sent by e-mail. Please submit your 
article via https://www.evise.com/profile/api/navigate/AFJEM 
 Submission Checklist  
You can use this list to carry out a final check of your submission before you send it to the 
journal for review. Please check the relevant section in this Guide for Authors for more 
details. 
Ensure that the following items are present:  
One author has been designated as the corresponding author with contact details:  
• E-mail address 
 • Full postal address  
All necessary files have been uploaded:  
Title page 
 Cover letter  
Manuscript: 
 • Include keywords 
• All figures (include relevant captions)  
• All tables (including titles, description, footnotes)  
• Ensure all figure and table citations in the text match the files provided  
• Indicate clearly if color should be used for any figures in print Graphical Abstracts / 
Highlights files (where applicable)  
Conflict of Interest Form  
Supplemental files (where applicable): Author Statement document and relevant reporting 
checklist 
 Further considerations • Manuscript has been 'spell checked' and 'grammar checked'  
• All references mentioned in the Reference List are cited in the text, and vice versa 
 • Permission has been obtained for use of copyrighted material from other sources 
(including the Internet) 
 • A competing interest’s statement is provided, even if the authors have no competing 
interests to declare 
 • Journal policies detailed in this guide have been reviewed  
• Referee suggestions and contact details provided, based on journal requirements 
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Title 
 
Metoclopramide vs Prochlorperazine for the treatment of nausea and vomiting in the 
emergency care setting: A scoping review  
  
Introduction to the study 
The South African EMS system is a 3 tiered system. EMS training is provided at a basic, 
intermediate and advanced level. Qualified practitioners have to be registered with the Health 
Professions Council to be able to practice. The current scope of practice only allows 
metoclopramide to treat nausea and vomiting in the prehospital setting, administered only by 
ALS providers. Treatment of nausea and vomiting is desirable to improve patient comfort 
during transport and help mitigate the complication risks such as dehydration, electrolyte 
abnormalities and aspiration. 
 
Background (Literature Review)  
Metoclopramide is a benzamide agent, gastroesophageal reflux disease, and post- operative 
nausea and vomiting used for the treatment of chemotherapy induced nausea and vomiting. 
It has the following side effect profile; EPS in more than 10% of patients receiving 
metoclopramide. Some other side effects are fatigue, restlessness, sedation, headache, 
dizziness, and somnolence. NMS, diarrhoea, impotence, nausea, menstrual disorders have 
also been reported, although the frequency of occurrence has not been established[55]. 
 
Prochlorperazine is a phenothiazine derivative agent[56]. Patients receiving prochlorperazine 
have reported experiencing the following side effects; insomnia, restlessness, dizziness, 
anxiety, euphoria, agitation, depression weakness and headache, constipation, dry mouth, 
blurred vision[56].  
 
There are few studies published that evaluates the medications used to treat nausea and 
vomiting in the prehospital environment and the emergency department. In a systematic 
review study done by Simpson Bendall and Middleton in 2011, where metoclopramide was 
compared to a placebo in the emergency care setting (either prehospital or in the emergency 
department), it was found that as many as 23% of patients receive metoclopramide for the 
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treatment of nausea and vomiting after they have received an opioid analgesic[57]. This study 
failed to provide rigorous evidence showing benefit to the patient after they have received 
metoclopramide[57]. They found no significant difference in vomiting when patients received 
either metoclopramide or a placebo. They concluded that the routine administration of 
metoclopramide to treat nausea might expose the patient to an unjustifiable risk of harm[57].   
 
In a prospective double blind randomised study done by Janet Talbot-Stern and Richard 
Paoloni in 1999; where prophylactic metoclopramide was administered to patients in the 
emergency department, it was found that 7.9% of the patients receiving metoclopramide 
experienced side effects not relating to nausea and vomiting[30]. The overall incidence of side 
effects in patients that have received metoclopramide is 11%[30]. The specific side effects 
reported by patients in the Talbot-Stern Paoloni study was restlessness, limb jerking, 
drowsiness, dizziness and vertigo[30].  
 
The current ALS guidelines have been published in September 2006[58]. The only drug listed 
for the treatment nausea and vomiting is Metoclopramide[58]. The HPCSA have recently 
compiled new clinical guidelines for prehospital practitioners’, but these are not yet approved  
for practice[59]. There information presented in the 2006 guidelines may be outdated. It 
recommends that the patient be given a bolus dosage of 10mg IVI to treat nausea and 
vomiting, yet studies have shown that if that same dosage is given as an infusion over 15 
minutes it has a 78% relative risk reduction in causing akathisia[60] 
 
Rationale  
Data from a private SA emergency medical service provider, from April 2012 up until January 
2017, shows their ALS paramedics had administered metoclopramide to 3.6% of their 
patients[61]. From a total of 48 023 patients that their ALS paramedics had treated, 1776 
patients received metoclopramide before admission to the emergency department[61].  
 
Vomiting exposes the patient to a higher risk of airway compromise and aspiration, because 
these patients are often lying supine in the back of the ambulance. The aspiration risk is 
exacerbated when these patients have been given a sedative in conjunction with the opioid 
analgesic (70% (1247) of the patients that received metoclopramide at ER24 had received an 
opioid analgesic). In order to appropriately manage these patients’ the ALS practitioner needs 
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to be able to treat this condition and prevent the patient from vomiting. It is noted that the 
above figure only represent data from one private emergency medical service in South Africa. 
This data is readily available from the above service provider.  
 
Metoclopramide has a blackbox warning because of the risk of tardive dyskinesia[55], yet it is 
the only drug made available to the ALS paramedics in South Africa to treat nausea and 
vomiting[58]. To effectively treat nausea and vomiting should employ a multinodal 
approach[56] and possibly the use of a safer more effective drug.   
 
 
Research Question 
What does the current scientific literature show comparing metoclopramide with 
prochlorperazine for the treatment of nausea and vomiting in the emergency care setting? 
 
 
 
Specific Aims 
To review the scientific literature comparing metoclopramide with prochlorperazine for the 
treatment of nausea and vomiting in the emergency care setting. 
 
Methods: 
Study design 
The scoping review methodology as described by Arksey and O’ Malley will be used to review 
and describe the literature [46]. A literature search will be done using Pubmed, Medline, 
Embase, Cochrane, Web of Science, and CINAHL online databases. Additionally, a web 
search through TRIP databases will be done to identify any grey literature. Lastly, a reference 
search of all included articles will be conducted to identify any literature not identified in the 
database search. A combination of MESH terms identified but not limited to nausea, vomiting, 
anti-emetic, emergency department, out-of-hospital, prehospital, emergency medical 
services, ambulance, ambulance service, metoclopramide, and prochlorperazine.  
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The results of the electronic database search will involve an initial title and abstract scan for 
the identification of relevant articles. This initial scan will be done by SA. The chosen articles 
will then undergo an independent review by IH to ensure rigor in the process.  Identified articles 
will be subjected to the inclusion and exclusion criteria to ensure that only relevant articles and 
studies have been chosen. PH will review the selection process and articles chosen to ensure 
that the process is transparent and reproducible.  
 
Study population and sampling 
All relevant studies that meet the inclusion criteria listed will be use where either 
Metoclopramide or Prochlorperazine was used for the treatment of nausea and vomiting in the 
prehospital or emergency department setting, will be considered for the review. 
The inclusion criteria for the studies is the date range January 1990 up to and including 
December 2016: 
1. Patient population of all ages (adult and paediatric) 
2. Research conducted in the prehospital setting 
3. Research conducted in the emergency department setting 
4. Studies where metoclopramide was compared to prochlorperazine in the prehospital 
environment or emergency care setting 
 
The exclusion criteria will be: 
1. Use of the study medication for illness/symptoms outside of nausea and vomiting 
2. Use of either metoclopramide or prochlorperazine outside of the emergency care 
setting  
3. Non-English language research 
 
Measurements and Results to be reported on 
A database will be created and the following data from included studies that will be collected 
and analysed: 
1. Study methodology; such as RCT, case-study, systematic review, prospective study 
2. Author of the study 
3. Years of study publication 
4. Study aim 
5. Study setting 
6. Study population  
7. Patient clinical data if provided 
8. Methods to assess nausea and/or vomiting pre/post intervention 
9. Drug administration protocol 
10. Time to relief of nausea/vomiting 
11. Adverse events reported by patients in the studies  
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12. Administration of rescue medication for the relief of nausea and vomiting 
 
Data management 
All data from the study will be entered into a Microsoft Excel 2013 database. This database 
will be password secured and protected. The data will saved in a shared folder between SA 
and IH. A further backup of the data will be saved onto a removable storage hard drive that 
SA will keep under lock and key. Access to the data on that drive will also be password secured 
and encrypted. 
 
Ethical considerations 
There is minimal ethical considerations because: 
1. There are no human or animal patients and /or participation in the study. 
2. No patient or participant information or data will be utilised in the study. 
3. All data recorded will be entered into a password protected worksheet that is only 
accessible to SA IH and PH 
4. Data will be backed up to a shared folder on Dropbox only accessible to SA IH and 
PH. Access will be protected by a password 
5. A secondary back up will be made onto an external hard drive that is password 
protected and encrypted that will only be accessible to SA and kept under lock and key 
 
 
 
 
Strengths and limitations 
SA acknowledges that this study will be subjected to the following biases[62]:  
1. Selection bias 
2. Publication  
3. Language bias 
This reason this study will be subjected to the above three biases is because of the time frame 
limitation attached to this review. A balance between the need to do further searching for 
articles and the additional costs incurred will  have to be done[62]. As a result of these biases 
and the time limitation attached to this review, not all studies conducted with metoclopramide 
or prochlorperazine will be included. SA also acknowledges that the available pool of evidence 
will biased as a result of publication and language bias  
 
The strengths of this research project is: 
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1. The project will be low cost 
2. This project can be used by the Professional Board of Emergency Care of the HPCSA 
and provide the ALS with an alternative drug to treat nausea and vomiting in the 
prehospital setting 
3. It will provide us with an understanding on the available research on the treatment of 
nausea and vomiting in the emergency care setting 
 
Project timeline 
2017  Aug Sep Oct Nov Dec Jan 
2018 
Feb
2018 
   
  
              
Sx-DRC  x x           
Ethics  X    X 
 
         
Gathering of 
studies 
  X X 
   
      
Transcribin
g of Data 
   X X X X 
  
    
Data 
Analysis 
    X X X  
   
  
Compilation 
of Final  
Report 
     X X    
  
 
Submission        X     
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Resources and budget 
Budget  
February – December 2013 
Item Description  Unit 
cost 
No 
of 
Uni
ts 
Total 
cost 
Consumables     
1. materials and 
supplies 
Printer paper   R500 
2. materials and 
supplies 
    
3. specialized services     
4. office supplies, 
printing & 
reproduction for data 
collection 
   R600 
5. office supplies, 
printing & 
reproduction for 
reports 
    
Research travel     
1. travel to sites     
2. other, specify INTERNET   700 
Minor research equipment     
1.      
2.      
3.      
Personnel     
1. Statistician     
2. Research 
Assistant(s) 
    
 
Sub-Total 
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Appendices 
Data extraction table 
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Study 
year Author Methodology Study Aim
Study 
Setting
Study 
Populati
on
 
• Methodology is the type of study is selected; if the study is a randomised control trial, 
a case-study, a systematic review or a prospective study 
• Study Aim is what the end points of the study was 
• Study setting is whether the study was conducted in the prehospital environment or 
in the emergency department 
• Study population describe if the study subjects were adults or paediatrics 
• Drug administered describes if metoclopramide or prochlorperazine or a placebo was 
administered 
• Dosage is the first dosage administered and the route of administration 
• Time to effect describes the length of time needed before the patient experienced 
relief from nausea and vomiting 
• Methods to assess nausea describes how nausea was assessed in the patient. If the 
researcher used  a visual analog scale or patient feedback 
 
 
 
 
